U.S. Patent No. 10,172,786 B2 (‘786) issued on January 8, 2019, for “Oral Care Composition Comprising Cannabinoids.” It was issued to applicant Axim Biotechnologies, Inc., of New York, New York. The inventors are George Anastassov of New York, New York, and Lekram Changoer of Ridderkerk, Netherlands. Axim is a cannabinoid pharmaceutical research company, known for CBD-based chewing gum, CANCHEW® and MEDCHEW®, to treat several ailments.
The ‘867 claims are directed to a composition for toothpaste comprising, among other ingredients, 0.1% – 0.5% by weight cannabidiol (CBD). In the specification, the stated problem that the invention addresses is having an oral hygiene product that containing a natural anti-bacterial additive, like one of the cannabinoids, CBD, CBG, or THC, since conventional anti-bacterial additives like triclosan and chlorhexidine actually increase anti-bacterial resistant bacteria to proliferate. The claimed invention, therefore, would be an improvement over the these conventional products.
The International Patent Classification is A61K (preparations for medical, dental purposes, namely (8/97) cosmetics or similar toilet preparations from algae, fungi, lichens or plants, (8/19) containing inorganic ingredients, or (8/25) silicon or compounds thereof, and (8/345) containing organic compounds containing oxygen, alcohols, or containing more than one hydroxyl group, and (8/731) containing organic macromolecular compounds, e.g., polysaccharides containing cellulose).
While there are many cannabinoid pharmaceutical companies, only a handful have actually received a granted patent. Axim has been successful in having one of their patent applications allowed. Please contact Yonaxis for more information on any of the IP processes described in this posting if you have any questions.